Satellos Bioscience Stock Today
| MSCLF Stock | USD 0.47 0.01 2.08% |
PerformanceWeak
| Odds Of DistressHigh
|
Satellos Bioscience is trading at 0.47 as of the 5th of December 2025. This is a 2.08 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.46. Satellos Bioscience has more than 69 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 6th of September 2025 and ending today, the 5th of December 2025. Click here to learn more.
Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. The company was incorporated in 2012 and is headquartered in Toronto, Canada. Satellos Bioscience operates under Biotechnology classification in the United States and is traded on OTC Exchange.. The company has 41.8 M outstanding shares. More on Satellos Bioscience
Moving against Satellos OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Satellos OTC Stock Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Satellos Bioscience [MSCLF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Satellos Bioscience's market, we take the total number of its shares issued and multiply it by Satellos Bioscience's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Satellos Bioscience classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 41.8 M outstanding shares.
Satellos Bioscience has accumulated about 1.93 M in cash with (5.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06.
Check Satellos Bioscience Probability Of Bankruptcy
Ownership AllocationSatellos Bioscience shows a total of 41.8 Million outstanding shares. Satellos Bioscience has 9.3 % of its outstanding shares held by insiders and 14.41 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Satellos Ownership Details
Satellos Bioscience Risk Profiles
| Mean Deviation | 2.99 | |||
| Semi Deviation | 3.23 | |||
| Standard Deviation | 3.99 | |||
| Variance | 15.89 |
Satellos Stock Against Markets
Picking the right benchmark for Satellos Bioscience otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Satellos Bioscience otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Satellos Bioscience is critical whether you are bullish or bearish towards Satellos Bioscience at a given time. Please also check how Satellos Bioscience's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Satellos Bioscience without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
Satellos Bioscience Corporate Management
Elected by the shareholders, the Satellos Bioscience's board of directors comprises two types of representatives: Satellos Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Satellos. The board's role is to monitor Satellos Bioscience's management team and ensure that shareholders' interests are well served. Satellos Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Satellos Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Rudnicki | CoFounder Officer | Profile | |
| CPA CMA | Chief Officer | Profile | |
| Philip MA | Chief Officer | Profile | |
| Robert CFA | VP Admin | Profile | |
| Francis MBA | CEO, CoFounder | Profile | |
| William Jarosz | Ex Director | Profile | |
| Bsc BSc | Strategic Advisor | Profile |
Other Information on Investing in Satellos OTC Stock
Satellos Bioscience financial ratios help investors to determine whether Satellos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Satellos with respect to the benefits of owning Satellos Bioscience security.